<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival </plain></SENT>
<SENT sid="1" pm="."><plain>Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies </plain></SENT>
<SENT sid="2" pm="."><plain>Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients </plain></SENT>
</text></document>